GPC3 and hepatocellular carcinoma: More recently, CAR‐T cells targeting glypican‐3 (GPC3) were reported to treat GPC3‐positive hepatocellular carcinoma (HCC) in clinical trials (NCT02715362, NCT03198546, and NCT02905188).